Клиника Inova первой в Вирджинии применила технологию флуоресцентной визуализации для выявления рака яичников

Inova has become the first health system in Virginia and the Mid-Atlantic region to use an FDA-approved fluorescent imaging technology designed to help surgeons identify ovarian cancer during surgery, providing an additional tool to locate and remove cancerous tissue. The technology, known as CYTALUX (pafolacianine), uses a fluorescent imaging agent administered intravenously before surgery. The agent binds to most ovarian cancer cells, causing them to illuminate when viewed with a specialized camera in the operating room. The technology can help surgeons detect cancerous tissue that may be difficult to visualize under standard operating room lighting. Inova surgeons performed the health system’s first ovarian cancer procedure using CYTALUX on July 8. “Ovarian cancer can be challenging because even very small areas of disease can be difficult to see during surgery, especially after chemotherapy, which many patients have started prior to surgery,” said Dr. Leslie Randall, director of Gynecologic Oncology at Inova Schar Cancer. “This technology provides another set of eyes in the operating room by illuminating cancerous tissue in real time. It helps us better visualize disease and supports our goal of removing as much visible cancer as possible for our patients.” Ovarian cancer is the deadliest gynecologic cancer in the United States, with nearly 20,000 women diagnosed and more than 12,000 deaths annually. The disease is frequently diagnosed at an advanced stage, when cancer has spread to multiple areas of the abdomen. Because cancerous tissue can be difficult to distinguish from healthy tissue during surgery, technologies that improve visualization may help surgeons identify additional areas of disease. During surgery, the fluorescent imaging agent highlights cancer cells under near-infrared light, allowing surgeons to evaluate tissue from a different perspective than conventional white-light visualization alone. In a clinical study led in part by Randall, use of the technology enabled surgeons to identify additional cancerous lesions that may otherwise have gone undetected in approximately 27% of patients. “At Inova, we’re committed to bringing the most advanced, evidence-based technologies to our patients as quickly and thoughtfully as possible,” said Dr. Larry Maxwell, president of Inova Women’s Services. “Innovations like fluorescent-guided imaging give our surgeons another powerful tool to better visualize cancer during surgery, supporting our goal of delivering the safest care and achieving the best possible outcomes for every patient.”